GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Guanhao Biotech Co Ltd (SZSE:300238) » Definitions » Cash Conversion Cycle

Guanhao Biotech Co (SZSE:300238) Cash Conversion Cycle : 273.36 (As of Mar. 2025)


View and export this data going back to 2011. Start your Free Trial

What is Guanhao Biotech Co Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Guanhao Biotech Co's Days Sales Outstanding for the three months ended in Mar. 2025 was 56.55.
Guanhao Biotech Co's Days Inventory for the three months ended in Mar. 2025 was 319.39.
Guanhao Biotech Co's Days Payable for the three months ended in Mar. 2025 was 102.58.
Therefore, Guanhao Biotech Co's Cash Conversion Cycle (CCC) for the three months ended in Mar. 2025 was 273.36.


Guanhao Biotech Co Cash Conversion Cycle Historical Data

The historical data trend for Guanhao Biotech Co's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guanhao Biotech Co Cash Conversion Cycle Chart

Guanhao Biotech Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only 423.91 477.02 490.00 280.30 258.65

Guanhao Biotech Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 302.53 318.33 403.53 332.57 273.36

Competitive Comparison of Guanhao Biotech Co's Cash Conversion Cycle

For the Biotechnology subindustry, Guanhao Biotech Co's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Guanhao Biotech Co's Cash Conversion Cycle Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Guanhao Biotech Co's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Guanhao Biotech Co's Cash Conversion Cycle falls into.


;
;

Guanhao Biotech Co Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Guanhao Biotech Co's Cash Conversion Cycle for the fiscal year that ended in Dec. 2024 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=58.35+353.25-152.95
=258.65

Guanhao Biotech Co's Cash Conversion Cycle for the quarter that ended in Mar. 2025 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=56.55+319.39-102.58
=273.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Guanhao Biotech Co  (SZSE:300238) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Guanhao Biotech Co Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Guanhao Biotech Co's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Guanhao Biotech Co Business Description

Traded in Other Exchanges
N/A
Address
No.12 Yuyan Road, Luogang District, Guangdong, Guangzhou, CHN, 510530
Guanhao Biotech Co Ltd is a China-based biotech company. It develops, manufactures and markets life and health-related products, with focus on regenerative medicines for the treatment of damaged tissue and organs. Its products include NormalGEN dura repair patch, GrandNeuro (Type B) dura repair patch, ThromalGEN (Type P) surgical patch, Guanhao-ACI, among others.
Executives
Liu De Wang Directors, executives
Zhao Jun Hui Directors, executives
Yang Guo Sheng Supervisors
Zhu Wei Ping Director
Hu Jun Securities Affairs Representative
Jia Bao Rong Executives
Jia Jun Chao Executives
Di Pu Director
Zhuo Fu Min Director
Guo Xiao Ming Executives
Zhang Hong Tao Executives
Zhao Wen Jie Executives
Guan Xin Director

Guanhao Biotech Co Headlines

No Headlines